{"filings":[{"id":96287,"accession_number":"0001628280-26-030522","cik":1855175,"company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Contineum reports Q1 net loss $14.5M; cash $246.3M through mid-2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities of $246.3M as of March 31, 2026; runway through mid-2029.","Net loss of $14.5M vs $16.0M in Q1 2025; R&D expenses down 15% to $11.6M.","Positive topline Phase 1b data for PIPE-791 in chronic pain (April 30, 2026); safety met and numeric pain improvement.","Initiated global Phase 2 PROPEL-IPF trial for PIPE-791 in IPF; target 324 patients; enrollment ongoing.","Johnson & Johnson Phase 2 Moonlight-1 trial of PIPE-307 in MDD recruiting 124 participants; completion expected June 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":502472891.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96286,"accession_number":"0001628280-26-028876","cik":1855175,"company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Contineum PIPE-791 Phase 1b shows safety, numeric pain reduction vs placebo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["43-patient crossover trial met primary safety endpoint; no serious AEs, most common TEAEs: headache (n=3), fatigue (n=2).","COAP patients: mean PI-NRS change -1.60 (PIPE-791) vs -1.27 (placebo) in Treatment Period 1.","CLBP patients: mean PI-NRS change -1.33 (PIPE-791) vs -0.55 (placebo) in Treatment Period 1.","Exploratory endpoints (≥30% pain reduction, KOOS) further supported positive PI-NRS trends.","Company plans further evaluation of PIPE-791 for chronic pain; also in Phase 2 PROPEL-IPF (IPF)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":502472891.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110042,"accession_number":"0001628280-26-015159","cik":1855175,"company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Contineum reports Q4 2025 net loss of $15.2M; upsizes ATM to $100M; Phase 2 IPF trial dosed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $15.2M vs $14.6M in Q4 2024; R&D expenses $12.8M, G&A $4.4M.","Cash and equivalents $262.9M; cash runway projected through mid-2029.","Initiated dosing in PROPEL-IPF Phase 2 trial of PIPE-791 for IPF (324 patients).","Amended ATM sales agreement to offer up to $100M in common stock; lock-up until March 11, 2026.","Topline data from PIPE-791 Phase 1b chronic pain trial expected Q2 2026; J&J Phase 2 MDD trial recruiting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":502472891.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110041,"accession_number":"0001437749-26-002072","cik":1855175,"company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Contineum Therapeutics approves 2026 Inducement Plan with 750,000 share reserve","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 2026 Employment Inducement Equity Incentive Plan on January 23, 2026.","Plan reserves 750,000 shares of Class A common stock for awards to new employees as inducement material.","Adopted without stockholder approval under Nasdaq Rule 5635(c)(4); no incentive stock options allowed.","Substantially similar to existing 2024 Equity Incentive Plan except for ISO prohibition and eligible recipients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":502472891.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126614,"accession_number":"0001437749-25-037842","cik":1855175,"company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Contineum prices upsized $90M public offering at $12.25/share; net proceeds ~$84.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["7,346,938 shares of Class A common stock sold at $12.25 per share, up from planned $75M.","Underwriters have a 30-day option to purchase up to 1,102,040 additional shares.","Net proceeds estimated at $84.2M after underwriting discounts and expenses.","Joint book-runners: Goldman Sachs, Leerink Partners, Stifel, RBC, William Blair; Jones as manager.","Offering closed December 15, 2025, with proceeds for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":502472891.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126613,"accession_number":"0001437749-25-037547","cik":1855175,"company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Contineum Therapeutics starts Phase 2 trial of PIPE-791 for IPF; 324 subjects, completion June 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Submitted Phase 2 trial details for PIPE-791 to ClinicalTrials.gov; expects ~324 IPF patients enrolled globally.","Trial is 26-week, randomized, dose-ranging, double-blind, placebo-controlled, once-daily dosing.","Primary efficacy endpoint: change from baseline in forced vital capacity (FVC) at week 26.","Trial design informed by regulatory feedback and completed Phase 1 data; completion expected June 2028.","No financial guidance or capital structure changes included in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":502472891.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126612,"accession_number":"0001437749-25-035860","cik":1855175,"company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Contineum's PIPE-307 Phase 2 RRMS trial misses primary endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 VISTA trial of M1 receptor antagonist PIPE-307 did not meet primary or secondary efficacy endpoints.","No significant change in binocular 2.5% low contrast letter acuity (LCLA) across treatment arms.","PIPE-307 demonstrated acceptable safety and tolerability at both doses.","Company will continue to analyze exploratory endpoints and plans future medical meeting presentation.","CEO and CMO express disappointment; focus remains on inflammatory and fibrotic disease pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":502472891.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126611,"accession_number":"0001437749-25-032422","cik":1855175,"company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Contineum Therapeutics Q3 net loss $12.8M, cash $182.4M, pipeline milestones affirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $182.4M; projected cash runway extended through 2028.","Net loss $12.8M vs $10.3M in prior-year quarter; R&D expenses $11.0M (+13% YoY).","Generated $19.0M from ATM offerings of 3.2M shares at weighted avg $6.04/share.","Topline data from PIPE-307 Phase 2 VISTA RRMS trial expected Q4 2025; global Phase 2 for PIPE-791 IPF to initiate Q4 2025.","Deferred initiation of PIPE-791 PrMS and CTX-343 trials to extend cash runway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":502472891.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143380,"accession_number":"0001437749-25-029349","cik":1855175,"company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Contineum reports positive Phase 1b PET data for PIPE-791; confirms target engagement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PIPE-791 achieved high LPA1 brain receptor occupancy in healthy volunteers and PrMS patients.","Plasma EC50 of 37 ng/mL at 24h and 12 ng/mL at 168h shows sustained target engagement.","Safety profile consistent with prior studies; no new safety signals identified.","Planned Phase 2 doses expected to exceed 90% target coverage at trough with once-daily dosing.","12 healthy volunteers and 4 PrMS patients enrolled; trial met primary PK/RO correlation objectives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":502472891.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143379,"accession_number":"0001437749-25-024849","cik":1855175,"company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Contineum Q2 net loss $16M, cash $175.5M; PIPE-307 VISTA top line data Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $16.0M for Q2 2025 vs $9.0M in Q2 2024; R&D expenses $14.1M (+78% YoY).","Cash and marketable securities $175.5M as of June 30, 2025; cash runway through 2027.","PIPE-307 Phase 2 VISTA (RRMS) top line data expected Q4 2025; PIPE-791 PET data Q3 2025.","Global PIPE-791 Phase 2 IPF trial initiation planned Q4 2025; PrMS and CTX-343 postponed.","Johnson & Johnson Phase 2 Moonlight-1 trial of PIPE-307 in MDD recruiting 124 participants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":502472891.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161535,"accession_number":"0001437749-25-021343","cik":1855175,"company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Contineum Therapeutics elects three Class I directors, ratifies EY as auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Sarah Boyce elected with 12.7M votes for vs. 641.9K withheld; broker non-votes 2.05M.","Troy Ignelzi elected with 13.2M votes for vs. 112.6K withheld; broker non-votes 2.05M.","Olivia Ware elected with 12.8M votes for vs. 583.7K withheld; broker non-votes 2.05M.","Ratification of Ernst & Young as auditor passed with 15.3M for, 53.9K against, 4.6K abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":502472891.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161534,"accession_number":"0001437749-25-016877","cik":1855175,"company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Contineum Q1 net loss $16.0M, cash $190.7M; files $300M shelf & $75M ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $16.0M vs $8.4M in Q1 2024; R&D expenses rose 76% to $13.7M.","Cash and equivalents of $190.7M; runway projected through 2027.","Files $300M universal shelf registration and $75M at-the-market (ATM) equity facility with Leerink Partners.","PIPE-791 Phase 1b PET topline data expected Q2 2025; Phase 2 initiation in IPF and PrMS planned H2 2025.","PIPE-307 Phase 2 VISTA RRMS topline data anticipated H2 2025; J&J Phase 2 MDD trial recruiting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":502472891.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161533,"accession_number":"0001437749-25-013334","cik":1855175,"company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Contineum Therapeutics appoints Timothy Watkins as CMO and Head of Development","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Watkins appointed Chief Medical Officer effective April 28, 2025, succeeding Dr. Stephen Huhn.","He previously served as VP and Therapeutic Area Head for Inflammation at Gilead Sciences.","Company plans to start Phase 2 proof-of-concept trial in IPF in H2 2025.","Received time-based option for 260,000 shares vesting over 42 months and performance-based option for 26,000 shares.","Grants are inducement awards under Nasdaq Listing Rule 5635(c)(4)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":502472891.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179688,"accession_number":"0001437749-25-007998","cik":1855175,"company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Contineum appoints Diego Miralles, M.D. to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Miralles appointed as Class II director effective March 14, 2025, term expiring at 2026 annual meeting.","He previously served as an advisor under an agreement with monthly retainer of up to $16,000 and an option for 5,000 shares at $17.92.","As a non-employee director, he will receive standard cash and equity compensation including an initial option grant for 29,500 shares.","Dr. Miralles is not considered independent under Nasdaq listing standards.","He currently serves as CEO of AZURNA Therapeutics and serves on the board of Artiva Biotherapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":502472891.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179687,"accession_number":"0001437749-25-006457","cik":1855175,"company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Contineum reports Q4 2024 net loss of $14.6M, cash $204.8M, runway through 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.6M in Q4 2024 vs $7.8M in Q4 2023; R&D expenses $13M (+62% YoY).","Cash and equivalents $204.8M at Dec 31, 2024; expects to fund operations through 2027.","Topline data from PIPE-791 Phase 1b PET trial expected Q2 2025; PIPE-307 Phase 2 RRMS data H2 2025.","PIPE-791 Phase 2 proof-of-concept in IPF and PrMS planned H2 2025 pending toxicity studies.","Plan to file IND for CTX-343 in H2 2025; J&J recruiting Phase 2 MDD trial of PIPE-307."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":502472891.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196428,"accession_number":"0001437749-24-033614","cik":1855175,"company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Contineum reports Q3 2024 cash $213.9M, VISTA trial enrollment on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $213.9M as of Sept 30, 2024 (vs $125.2M at end of 2023).","R&D expense $9.7M (+$3.2M YoY) driven by VISTA Phase 2 trial and PIPE-791 toxicology studies.","VISTA trial for PIPE-307 in RRMS two-thirds enrolled; full enrollment expected first half 2025.","Pending MHRA authorization, Phase 1b PET trial for PIPE-791 to start Dec 2024 with data in H1 2025.","Janssen confirms on track to initiate Phase 2 trial of PIPE-307 in depression."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":502472891.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212722,"accession_number":"0001437749-24-026664","cik":1855175,"company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","form_type":"8-K/A","filed_at":"2024-08-14T23:59:59+00:00","items":["9.01","2.02","7.01"],"status":"ready","headline":"Contineum Q2 cash $218.7M; R&D $7.9M; IPO net $107.9M; Phase 2 enrollment on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $218.7M at June 30, 2024, up from $125.2M at YE 2023.","R&D expenses $7.9M in Q2, down from $9.5M YoY, driven by lower consulting/manufacturing offset by Phase 2 costs.","G&A expenses $3.0M, up from $1.6M YoY on higher consulting and personnel costs.","IPO completed in April 2024 with net proceeds of $107.9M.","Enrollment ongoing in Phase 2 VISTA trial of PIPE-307 for RRMS; expects completion in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":502472891.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212723,"accession_number":"0001437749-24-026385","cik":1855175,"company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Contineum Q2 cash $218.7M; PIPE-307 Phase 2 enrollment on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $218.7M at June 30, 2024, up from $125.2M at year-end 2023.","R&D expenses $7.9M vs $9.5M YoY; G&A expenses $3.0M vs $1.6M YoY.","Completed IPO in April 2024, net proceeds $107.9M.","Phase 2 VISTA trial of PIPE-307 for RRMS enrollment on track, completion expected in 2025.","Strengthened board and management with four new appointments, including Troy Ignelzi and Sarah Boyce."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":502472891.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231754,"accession_number":"0001437749-24-021083","cik":1855175,"company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Contineum Therapeutics appoints Sarah Boyce to Board, effective June 24, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sarah Boyce appointed as Class I director and Chair of Nominating and Corporate Governance Committee.","Boyce currently President & CEO of Avidity Biosciences (RNA); past roles include Akcea, Ionis, Forest Labs.","As non-employee director, receives standard compensation including initial option for 29,500 Class A shares.","Replaces Lori Lyons-Williams as Committee Chair; Lyons-Williams remains a member of the committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":502472891.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231753,"accession_number":"0001437749-24-018934","cik":1855175,"company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Contineum Therapeutics adopts Executive Severance Plan for named executive officers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Carmine Stengone designated Tier 1 participant; CSO Lorrain, CFO Slover designated Tier 2 participants.","Non-CIC severance: 12 months base salary + pro-rata bonus; health coverage up to 12 months.","CIC severance: 150% (Tier1) or 100% (Tier2) of salary+bonus; equity acceleration; health to 18/12 mo.","Plan replaces prior severance agreements; participants must sign release and arbitration agreement.","Plan effective May 24; participation agreements executed May 28, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":502472891.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231752,"accession_number":"0001437749-24-017651","cik":1855175,"company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Contineum Therapeutics appoints Troy Ignelzi to board as Audit Committee Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Troy Ignelzi appointed as Class I director and Chair of Audit Committee, effective May 20, 2024.","Evert Schimmelpennink stepped down from Audit Committee; Class I directors now Ignelzi and Olivia Ware.","Ignelzi is CFO of Rapport Therapeutics; previously CFO at Karuna Therapeutics, scPharma, Juventas.","Ignelzi will receive standard non-employee director compensation including an option for 23,150 shares.","Board determined Ignelzi independent and an audit committee financial expert under SEC/Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":502472891.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231751,"accession_number":"0001437749-24-017293","cik":1855175,"company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Contineum Q1 2024 cash $117.9M; IPO net proceeds $108M extend runway to 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and securities $117.9M at March 31; proforma cash (incl. IPO) $225.9M.","R&D expenses $7.8M vs $3.6M YoY; increase driven by product candidate development.","Completed IPO in April 2024; net proceeds $108.0M, extending cash runway to end of 2027.","Initiated Phase 2 trial of PIPE-307 in RRMS; J&J partner plans Phase 2 in depression in 2024.","Nominated third development candidate CTX-343 (LPA1R antagonist); IND submission expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":502472891.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231750,"accession_number":"0001193125-24-090917","cik":1855175,"company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Contineum Therapeutics adopts amended charter and bylaws upon IPO closing","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Authorized 200M Class A common and 20M Class B common shares, plus 10M undesignated preferred.","Classified board with staggered three-year terms; directors removable only for cause with 66 2/3% vote.","Exclusive forum: Delaware Chancery for derivative/breach claims; federal courts for Securities Act claims.","Stockholders cannot act by written consent or call special meetings; new procedures for proposals and nominations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":502472891.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}